期刊文献+

局部注射雷株单抗治疗糖尿病视网膜病变的临床观察

Clinical observation of local injection of ranibizumab in the treatment of diabetic retinopathy
下载PDF
导出
摘要 目的观察局部注射雷株单抗治疗糖尿病视网膜病变的临床效果。方法分析2012年1月~2013年12月在本院眼科确诊为糖尿病视网膜病变的38例患者40只眼,接受局部注射雷株单抗,对比治疗前和治疗矫正12周后的最佳矫正视力(BCVA)、黄斑中心视网膜厚度(CRT)和黄斑总体积(TMV)的变化情况。结果治疗前BCVA平均字母数为37.11±14.27,黄斑CRT为(535.16±218.37)μm,TMV为(13.70±1.67)mm^3;治疗12周后,BCVA平均字母数为46.57±15.17,黄斑CRT为(431.27±171.26)μm,TMV为(9.24±2.07)mm^3,治疗前后比较,差异有统计学意义(P〈0.05)。所有患者在治疗期间均未见明显严重不良事件。结论局部注射雷株单抗治疗糖尿病视网膜病变,能够减小黄斑CRT和TMV,进而提高患眼视力,疗效确切。 Objective To observe the clinical efficacy of local injection of ranibizumab in the treatment of diabetic retinopathy. Methods 38 cases of diabetic retinopathy in 40 eyes confirmed in Department of Ophthalmology of our hospital from January 2012 to December 2013 were analyzed.Local injection ranibizumab was used,and best corrected visual acuity(BCVA),macular central retinal thickness(CRT) and macular total macular volume(TMV) before treatment and after 12 weeks treatment was compared. Results Before treatment,38 patients(40 eyes) of the BCVA was 37.11 ±14.27 average number of letters,CRT was(535.16±218.37) μm,TMV was(13.70±1.67) mm3;After 12 weeks treatment,the BCVA was 46.57±15.17 average number of letters,CRT was(431.27±171.26) μm,TMV was(9.24±2.07) mm3,the difference was significant before and after treatment(P〈0.05).There were no adverse reaction occurred during treatment.Conclusion Local injection of ranibizumab in the treatment of diabetic retinopathy can reduce the macular CRT and TMV,can improve the visual acuities,the effect is curative.
作者 吴棕波
出处 《中国当代医药》 2014年第33期157-158,161,共3页 China Modern Medicine
关键词 糖尿病视网膜病变 雷珠单抗 局部注射 黄斑 Diabetic retinopathy Ranibizumab Local injection Macular
  • 相关文献

参考文献11

  • 1Porta M,Allione A.Current approaches and perspectives in the medical treatment of diabetic retinopathy[J].Pharmacol Ther,2004,103(2) : 167-77.
  • 2吴方来,汪四虎,黄大祥,伯伟.前列地尔治疗早期糖尿病视网膜病变的临床观察[J].中国当代医药,2011,18(33):70-71. 被引量:11
  • 3韩永杰.糖尿病视网膜病变与血清VEGF和TNF-α水平的相关性研究[J].中国当代医药,2011,18(25):27-28. 被引量:1
  • 4Ip MS, Bressler SB,Antoszyk AN,et al.A randomized trial comparing intravitreal triamcinolone and focal/grid photo- coagulation for diabetic macular edema:baseline features [J].Retina, 2008,28 (7) :919-930.
  • 5Strom C ,Sander B,Klemp K,et al.Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema[J].Invest Ophthalmol Vis Sci, 2005,46 (10) : 3855-3858.
  • 6Ikagawa H,Yoneda M ,Iwaki M,et al.Chemical toxicity of indocyanine green damages retinal pigment epithelium[J]. Invest Ophthalmol Vis Sci ,2005,46(7) :2531-2539.
  • 7Yilmaz T, Weaver CD, Gallagher MJ,et al.Intravitreal tri- amcinolone aeetonide injection for treatment of refractory diabetic macular edema:a systematic review [J].Ophthal- mology, 2009,116(5) :902-911,912-913.
  • 8Jamrozy-Witkowska A,Grabska-Liberek I,Kowalska K,et ol. Endophthalmitis following intravitreal triameinolone ace- tonid injection a case report [J].Klin Oczna,2010,112 ( 1-3 ) : 57-60.
  • 9Funatsu H,Noma H,Mimura T,et al.Assoeiation of vitre- ous inflammatory factors with diabetic macular edema[J]. Ophthalmology, 2009,116 ( 1 ) : 73-79.
  • 10Avery RL, Pieramici D J, Rabena MD,et al.Intravitreal be- vacizumab (Avastin) fomeovascular age-related macular degeneration[J].Ophthalmology, 2006,113 (3) : 363 -372.

二级参考文献12

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部